Avecho advances final insomnia trial stage as global licensing interest builds

Final Phase III insomnia cohort returns to recruitment

Avecho Biotechnology Limited (ASX:AVE) has restarted recruitment and dosing for the final stage of its pivotal Phase III trial of a TPM-enhanced cannabidiol capsule for insomnia, putting its lead program back into execution after a positive interim review.

The independent Data Monitoring Board assessed unblinded data from the first 244 participants and unanimously recommended that the study continue to its original target of 519 participants completing treatment, without increasing the planned sample size. Avecho remains blinded to treatment allocation and efficacy results, so the interim review does not establish whether the capsule improves insomnia outcomes.

Approximately 320 further participants are expected to be enrolled, including allowance for withdrawals. The company says additional sites are being progressively activated and that recruitment could be completed within about 12 months once the expanded network is operational. The trial compares nightly 75mg and 150mg CBD doses with placebo over eight weeks, using validated questionnaires and daily sleep diaries.

Safety review clears route to commercial discussions

No serious adverse events were identified among the 244 participants assessed across the three treatment groups. That is a useful safety signal, although it is not an efficacy result and the final clinical readout remains ahead. Successful completion would be the final clinical step supporting a potential application to the Australian Therapeutic Goods Administration for registration of the capsule.

The update builds on the August Phase III recruitment restart, when Avecho reported the same interim recommendation and safety finding. The current filing adds the operational detail that the final cohort is now being recruited through the existing clinical network, with further sites intended to accelerate enrolment.

Licensing push gains senior business development support

Avecho says discussions with multiple pharmaceutical companies for territories outside Australia have continued to advance. It has appointed Eve Williamson, a former global business development leader at CSL, as a strategic consultant to help assess licensing, partnering, co-development and commercialisation opportunities for the CBD capsule and other assets.

The company will hold scheduled meetings with prospective partners at BIO-Europe in November. It prefers non-dilutive licensing income to fund the activation of additional clinical sites, but explicitly cautions that discussions may not result in a transaction and that any timing or terms remain uncertain. Avecho is also continuing work with Sandoz on activities supporting a future TGA submission.

Cash runway makes licensing timing material

Avecho ended September with $5.275 million in cash, compared with $6.610 million three months earlier. Operating cash use was $1.770 million for the quarter, while a $477,000 draw under an R&D loan facility provided additional funding pending the company’s R&D tax incentive.

On the Appendix 4C calculation, that cash balance represented an estimated 2.98 quarters of funding at the quarter’s operating cash-use rate. It is a mechanical estimate rather than a forecast, and the company’s stated preference for licensing proceeds to support extra trial sites makes the timing of any partnership commercially important. A Japanese patent granted during the quarter strengthens protection for the capsule through 2041, alongside corresponding United States and European patents, but intellectual property protection does not itself resolve the funding or regulatory milestones still ahead.